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Abstract
Background: Prescribing, monitoring and administration of medicines in care homes could be improved. A cluster
randomised controlled trial (RCT) is ongoing to evaluate the effectiveness of an independent prescribing pharmacist
assuming responsibility for medicines management in care homes compared to usual care.
Aims and Objectives: To conduct a mixed-methods process evaluation of the RCT, in line with Medical Research
Council (MRC) process evaluation guidance, to inform interpretation of main trial findings and if the service is found
to be effective and efficient, to inform subsequent implementation.
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Objectives:
1. To describe the intervention as delivered in terms of quality, quantity, adaptations and variations across triads
and time.
2. To explore the effects of individual intervention components on the primary outcomes.
3. To investigate the mechanisms of impact.
4. To describe the perceived effectiveness of relevant intervention components [including pharmacist
independent prescriber (PIP) training and care home staff training] from participant [general practitioner (GP),
care home, PIP and resident/relative] perspectives.
5. To describe the characteristics of GP, care home, PIP and resident participants to assess reach.
6. To estimate the extent to which intervention delivery is normalised among the intervention healthcare
professionals and related practice staff.
Methods: A mix of quantitative (surveys, record reviews) and qualitative (interviews) approaches will be used to
collect data on the extent of the delivery of detailed tasks required to implement the new service, to collect data to
confirm the mechanism of impact as hypothesised in the logic model, to collect explanatory process and final
outcome data, and data on contextual factors which could have facilitated or hindered effective and efficient
delivery of the service.
Discussion: Recruitment is ongoing and the trial should complete in early 2020. The systematic and
comprehensive approach that is being adopted will ensure data is captured on all aspects of the study, and allow a
full understanding of the implementation of the service and the RCT findings. With so many interrelated factors
involved it is important that a process evaluation is undertaken to enable us to identify which elements of the
service were deemed to be effective, explain any differences seen, and identify enablers, barriers and future
adaptions.
Trial registration: ISRCTN17847169.
Date registered: 15 December 2017.
Keywords: Older people, pharmacist prescribing, care homes, polypharmacy, randomised controlled trial
Introduction
Medication management in care homes is suboptimal
[1]. Despite various policy recommendations [2–7], the
majority of care home residents continue to receive in-
appropriate medication, and a significant number of ad-
ministration errors occur [8]. Many residents are on
multiple medications, and there is overuse of psycho-
tropic medicines, as well as more general concern such
as lack of biochemical monitoring of high-risk drugs in-
cluding methotrexate, azathioprine, amiodarone, war-
farin etc. and lack of regular medication review [9].
Further, there is often poor communication between
general practitioner (GPs), care home staff, community
pharmacists, residents and their relatives, and a need for
training of care home staff, many of whom may not have
a theoretical understanding of the requirements for sup-
ply, storage, recording and administration of medicines.
High staff turnover and the frailty of the resident popu-
lation are further factors. It has been suggested that er-
rors would be reduced if a single person took on overall
responsibility for the medicines management in care
homes. Our team proposed this should be a pharmacist
independent prescriber (PIP) linked to the care home,
and are undertaking a programme of work which has
identified logistical and professional barriers to a PIP
care home service, and devised solutions to address
them [10], devised a training programme for the PIPs to
ensure they have the requisite competencies to deliver
the service, and identified provisional measures of out-
come [11] in preparation for a definitive cluster rando-
mised controlled trial (RCT) to compare the outcomes
from the PIP service with usual care. A mixed-methods
non-randomised feasibility study [12] confirmed the ac-
ceptability and feasibility of the processes for participant
identification, recruitment and informed consent. The
PIP service was found to be acceptable to all stake-
holders and benefits were reported by GPs and care
home staff. Appropriate outcome measures and tools
were confirmed and minor refinements were made to
the service specification and RCT protocol. The defini-
tive cluster RCT is ongoing and will complete in May
2020. An internal pilot within the definitive trial has
confirmed: (i) the feasibility of recruiting and randomis-
ing sufficient GP practices, PIPs, care homes and resi-
dents; (ii) the availability of data for primary outcome at
3 months; (iii) confirmation that there are no
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intervention-related safety concerns and (iv) researcher
blinding and unblinding [12].
The definitive RCT was approved by ethics commit-
tees in England and Scotland, and registered with the
ISRCTN registry (registration number ISRCTN
17847169). A protocol paper (protocol version 5 1.7.18)
for the main trial, following SPIRIT guidance, has been
submitted to BMC Trials [13]. This current article de-
scribes the protocol for the Process Evaluation Protocol
that accompanies the definitive RCT; it follows the 2014
guidance on process evaluations [14, 15] and details are
in Process Evaluation Protocol version 4 11.12.18 avail-
able from the authors on request.
Causal assumptions
The definitive RCT is evaluating the efficacy and efficiency
of implementing and delivering a PIP service and compar-
ing outcomes for care home residents who receive the PIP
service with outcomes for residents who continue to re-
ceive usual care [13]. In total 44 GP/PIP/care home
groups (subsequently referred to as triads) and 880 pa-
tients will be included in four geographical areas of East
Anglia, Leeds, North East Scotland and Northern Ireland.
As noted above, the problem is that medicines manage-
ment in care homes is suboptimal and complex, because
the frailty and comorbidities of residents means many are
on multiple medications. A logic model was developed
(Additional file 1: Appendix 1) to demonstrate how the
proposed PIP service could address the various issues. The
PIP intervention is described below.
The intervention
At intervention care home(s), PIPs working in collabor-
ation with the relevant GP(s), will assume responsibility
for the medicines management of a mean of 20 care
home residents living in one or more care homes associ-
ated with the GP practice. To ensure competency in
professional role and study procedures, the recruited
PIPs are qualified independent prescribers, and have
attended a 2-day face-to-face training programme, which
included an overview of the trial design, project delivery,
and preparation for the role; the service specification
and completion of the Pharmaceutical Care Plans
(PCPs). This was followed by time to develop relation-
ships with medical practices (for those unfamiliar with
the practice), care homes and community pharmacists,
including performing medication reviews with GPs and
observing medication administration by care staff, before
final sign-off by clinically qualified professionals inde-
pendent of the research team.
A service specification for the PIPs has been developed
iteratively in the earlier stages of the project, and is at-
tached (Additional file 1: Appendix 2). In summary, it
includes:
 reviewing a participating resident’s medication and
developing and implementing a PCP
 assuming prescribing responsibilities
 supporting systematic ordering, prescribing and
administration processes within each care home, GP
practice and supplying pharmacy where needed
 providing training to staff in care home and GP
practice
 communicating with GP practice, care home,
supplying community pharmacy and study team
The control arm
At each control care home, medicine management is ac-
cording to usual practice, in which the GP(s) has respon-
sibility for the medicines management of care home
residents living in one or more care homes associated
with the GP practice. Pharmacy provision is also accord-
ing to usual practice in that area.
The CHIPPS RCT process evaluation
The aims of the process evaluation, described in this art-
icle are informed by the logic model and the stages of
the Medical Research Council (MRC) process evaluation
framework [14, 15]. These are listed below.
1. To describe the intervention as delivered in terms
of quality, quantity, adaptations and variations
across triads and time (Table 1).
2. To explore the effects of individual intervention
components on the primary outcomes (Tables 2
and 3).
3. To investigate the mechanisms of impact (Table 2).
4. To describe the perceived effectiveness of relevant
intervention components (including PIP training
and care home staff training) from participant (GP,
care home, PIP and resident/relative) perspectives
(Tables 2, 3 and 4).
5. To describe the characteristics of GP, care home,
PIP and resident participants to assess reach
(Table 4).
6. To estimate the extent to which intervention
delivery is normalised among the intervention
healthcare professionals and related practice staff
(Table 4).
7. If the service is found to be effective and efficient,
to inform subsequent implementation.
Methods
Design
In line with the MRC guidance on process evaluation
[14, 15] this mixed-methods process evaluation using
qualitative and quantitative approaches will collect data
on implementation of the intervention, mechanisms of
impact, outcomes and contextual factors. The tasks,
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aims, data and data source for each of these are sum-
marised in Tables 1, 2, 3, 4. All data is collected, from
intervention arm participants only, after the 6-month
study period is completed for an individual participant.
Implementation
Data will be collected on the effectiveness of the train-
ing, and the services delivered by the PIPs (see Table 1
below) to provide an understanding of whether the PIPS
were adequately prepared for the role and the fidelity
with which it was delivered.
Mechanism of impact
Data will be collected to confirm the mechanism of im-
pact of the intervention in achieving the desired aim of
improved patient quality of care (Table 2). This section
draws particularly on the logic model and hypotheses for
addressing the highlighted issues. Data will only be col-
lected from the intervention group to see if any observed
differences in outcomes between the groups can be ex-
plained by different components of the PIP service.
None of these happen in the control (usual care) group.
Outcomes
The outcomes that are collected and which will be used in
the process evaluation are described in Table 3. The selected
outcomes are those where there is a clear link to the inter-
vention proposed and where they inform the process.
Contextual factors
Any contextual factors identified which might have af-
fected the delivery and impact of the intervention are
described in Table 4. This information may include fac-
tors related to individual personnel and organisations as
well as macro-level issues such as Care Quality Commis-
sion requirements or head office requirements.
Data collection methods
The following text refers to the data sources identified
in Tables 1–4 .
Quantitative
Data sources related to training and pharmacist
competency
 Training feedback: At each PIP training event, PIPs
are asked to complete a feedback form at the end of
the 2-day face-to-face session
 Pre-intervention competency: Following the training,
PIPs submit their competency framework to one of
the study competency assessors who discuss these
with the PIP and signs them off as ‘fit to practise’ as
a CHIPPS PIP, prescribes further training or that
they are not competent to deliver the study
 Review of PCPs: Following an agreed process (Additional
file 1: Appendices 3 and 4) a random 20% of PCPs are
reviewed for appropriateness by study team members
who are specialists in care of the elderly. Whilst this
process is primarily about safety, the assessment
templates also capture data on missed opportunities.
Data sources related to activity
 PIP activity log: Intervention PIPs are asked to keep
an activity log of their daily activity detailing the
time spent on tasks as listed in the service
specification (Additional file 1: Appendix 2)
 PIP survey: Following each phase, intervention PIPs
will be asked to complete a short questionnaire
asking about their experiences and the extent to
which they delivered aspects of the intervention
focusing especially on non-medication review
Table 1 Implementation tasks and data collected as part of process evaluation
Task Aim (what is being assessed) Data collected Data source
Provide training for
PIPs
Effectiveness of training PIP views on training Post- training feedback forms
(at end of 2-day training session)
PIP interview
PIP questionnaire
Competency Competency assessments (feedback from
independent assessors)
Appropriateness of PCPs (20% sample; Additional file
1: Appendices 3,4)
Views of stakeholders (interviews)
PIP delivery of the
intervention
Fidelity to intervention Services provided and frequency with
which provided
PIP activity logs
Number of pharmaceutical care plans
PIP questionnaire
Quality of medication review Review of 20% of pharmaceutical care plans
PCP Pharmaceutical Care Plan; PIP pharmacist independent prescriber
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aspects of the service specification (the NoMAD sur-
vey [16]).
Data sources related to prescribing
Most of the prescribing-associated data is collected as
part of the main trial processes to assess effectiveness
and efficiency of the intervention (GP records, health-
care utilisation, falls records, hospitalisations and deaths)
and processes are detailed in the main trial protocol
(version 5 1.7.18). The following lists additional data col-
lected as part of the process evaluation
 Adverse events: Adverse events which are not
deemed serious are reported using a standard
template emailed to the Clinical Trials Unit. All
study participants with a professional role (PIP GP,
GP staff and care home staff) are made aware of this
template and are asked to use this facility if they
Table 2 Mechanism of impact and data collected as part of process evaluation
Impact Mechanism of impact Data collected Data source
Medication changes identified PIP medication review Recommendations for change and
rationale
Pharmaceutical
care plans
PIP interview
PIP questionnaire
Medication changes made PIP prescribing Total no. medications per patient at
baseline and 6months
Pharmaceutical
care plans
GP records
No. medications stopped per patient at 6
months
Pharmaceutical
care plans
GP records
No. medications started per patient at 6
months
Pharmaceutical
care plans
GP records
No. medications amended, e.g. dose
change, formulation change
Pharmaceutical
care plans
GP records
No. antipsychotics/psychotropics
prescribed at baseline and 6months
Pharmaceutical
care plans
GP records
Categorised description of drugs changed,
stopped, started
Resident medical
records
Biochemical monitoring PIP medication review Recommendations made for biochemical
monitoring
Pharmaceutical
care plans
Medication errors PIP medication review Number of prescribing, dispensing and
administration errors
Pharmaceutical
care plans
GP records
Non-patient-facing activities improved, e.g. medication
storage advice
PIP support for care
home
Services provided and frequency PIP activity log
Views on usefulness of services Care home staff
interviews
PIP interview
PIP questionnaire
Better/tailored training for staff PIP training for care
home staff
Training provided and frequency PIP activity log
Views on usefulness of training Care home staff
interviews
PIP interview
PIP questionnaire
Quality of communication between care home, GP and
community pharmacy improved
PIP input into improved
communication
Views of care home staff Care home staff
interviews
Views of GPs GP interview
Views of PIPs PIP interview
PIP questionnaire
GP general practitioner; PIP pharmacist independent prescriber
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suspect any adverse event, whether or not there is a
perceived causal relationship with the intervention
 PCPs: these are completed by the PIP as a clinical
record of their actions including the rationale for
these. Data extraction from these will inform the
details of medication changes that underpin the
global measures such as total number of medicines,
British National Formulary categories most involved
in changes, and overall Drug Burden Index (DBI).
They will also include information on homely
remedies and medications available from pharmacies
(P medicines) and other retail outlets (general sale
list medicines) which could result in therapeutic
duplication
Data sources related to variability
Variability may be due to inherent non-modifiable
differences across participating organisations, sites and
individuals, or to the way the CHIPPS service has
been delivered or normalised. The former will be ex-
plored using subgroup analyses and the latter by gen-
eral estimating equations (GEEs) and applying
normalisation process theory (NPT) via a NoMAD
[16] survey to all participating GPs, PIPS and care
home staff at the end of each phase. These are de-
scribed below.
 Subgroup analyses: The following subgroup analyses
will be conducted.
i. Comparison of intervention effect by care home
types, i.e. nursing versus residential.
ii. Comparison of intervention effect by the
employment status of the PIPs, i.e. those PIPs
who were previously employed, and therefore
had an established working relationship, with the
study GP practice, and those who were not).
For both of the above an interaction term (between
treatment and subgrouping factor) will be added to
Table 3 Outcomes and data collected as part of process evaluation
Aim Outcome Data collected Data source
To improve quality of care for
those over 65 years old resident in
care homes
Falls Fall rate per person at 3 months Care home falls record
Fall rate per person at 6 months Care home falls record
Quality of life Self-reported quality of life Face-to-face self-reported EQ-5D-5 L (only applicable
for participants with capacity) at baseline, 3 months
and 6 months
Carer-assessed quality of life Proxy EQ-5D-5 L (quality of life) at baseline, 3 months
and 6 months
Physical functioning Carer-assessed physical
functioning
Proxy Barthel Index (physical functioning) at baseline
and 6 months
Health service
utilisation and
associated costs
Costs of care (medication,
healthcare team contacts,
monitoring and tests)
GP records at baseline and 6months
DBI Calculate DBI based on
medications
GP records at baseline and 6months
To assess intervention safety Mortality Information on numbers dying
and time to death.
Monthly call to care homes
Hospitalisations
(Note: not always a
negative marker of
safety)
Information on numbers
hospitalised
Monthly call to care homes
Global viewa Perceptions of GPs GP interview
Perceptions of care home staff Care home staff interviews
Perception of residents/
consultee/WPOA
Resident/consultee/WPOA interviews
Perceptions of PIPs PIP interview
Adverse eventsa New drug related symptoms Stakeholder feedback using standard template
Serious adverse
eventsa
See hospitalisations/deaths Monthly call to care homes
Sudden unexpected
serious adverse
eventsa
See hospitalisations/deaths Feedback from GPs/independent medical assessor on
causal link with PIP intervention
DBI Drug Burden Index; EQ-5D-5 L EuroQoL five-dimension, five-level questionnaire; GP general practitioner; PIP pharmacist independent prescriber; WPOA Welfare
Power of Attorney
a Other than those noted, these are also primary and secondary outcomes for main trial and will be compared across groups
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the primary model and formally tested for a non-
zero value.
 GEEs: Any effect of the PIP intervention is likely to
be mediated through a decrease in the DBI. This
will be tested using a GEE, adjusting for group
membership (this is in order to remove any effect of
the PIP intervention on falls mediated via a different
causal route).
 NoMAD survey [16]: The NoMAD survey is an
implementation measure based on the
Normalisation Process Theory (NPT) [17, 18]. The
survey form includes preliminary demography and
Table 4 Contextual factors collected as part of process evaluation
Contextual factor Data collected Data source
Barriers to delivering the
intervention
Feedback from stakeholders Care home staff interview
GP interview
PIP interview
NoMAD [16] survey to GPs/PIPs and
care home staff
Other anecdotal feedback
Facilitators to delivering the
intervention
Feedback from stakeholders Care home staff interviews
GP interview
PIP interview
NoMAD [16] survey to GPs/PIPs and
care home staff
Other anecdotal feedback
Site and participant factors Inter PIP variation Competency Variation in outcomes
Review of PCPs for both safety and
missed opportunity
GP interview
Care home interviews
Employment status Baseline PIP questionnaire
Qualifications Baseline PIP questionnaire
Inter-site variation Care home factors Baseline care home survey
Resident factors Baseline resident data
Inter-location variation Views of researchers Meeting minutes
Normalisation of intervention
into routine practice
Actions taken by participants to ensure
the intervention works
Coherence
(Making sense of the service)
NoMAD survey [16] to PIPs, care
home staff, GPs
GP interview
Care home staff interviews
PIP interview
Cognitive participation
(Engaging with the service)
NoMAD [16] survey to PIP, care
home staff, GPs
Interviews (GP and care home staff)
PIP interview
Collective action
(delivering the service/
responding to the service)
NoMAD [16] survey to PIP, care
home staff, GPs
GP interview
Care home staff interviews
PIP interview
Reflexive monitoring
(appraising and reviewing the
service)
NoMAD [16] survey to PIP, care
home staff, GPs
GP interview
Care home staff interviews
PIP interview
GP general practitioner; PIP pharmacist independent prescriber
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general questions about experiences and satisfaction
followed by four sections each relating to one of the
NPT domains of coherence, cognitive participation,
collective action and reflexive monitoring.
Qualitative
Feedback from all stakeholders on their experiences and
views of the intervention is a core part of this process
evaluation. This will help contextualise the intervention
and increase understanding of the process of implemen-
tation and any variation between sites and stakeholders.
Interviews
At the end of each phase of the intervention a purposive
sample of up to three of each of GPs, care home man-
agers, staff, residents and relatives (if available) in each
of the four geographical areas will be invited to take part
in a semi-structured interview. Sampling will be based
on a maximum variation sample to reflect differences in
site and PIP characteristics, e.g. PIP employment status,
previous PIP experience, demographic profile of care
home residents, rural or urban location. All PIPS will be
invited to take part in an interview.
Interviews will be guided by a topic guide (Additional
file 1: Appendix 5), developed from the qualitative out-
puts from the earlier non-randomised feasibility study
[12]. Topics will include participants’ views of the PIP
service implementation and delivery, communication be-
tween staff, perceived effectiveness of the intervention
and the identification of any unintentional conse-
quences. All aspects of the service will be probed and
there will be specific probes for unforeseen effects to
understand whether anything else about the service im-
pacted positively or negatively on patient care or cost-
effectiveness. In addition to the above topics, the PIP
interview will explore their perception of the training
programme and its utility.
Conduct and analysis
All participants invited to interview will be given an in-
formation sheet and consent form prior to participation.
Ideally, interviews will be held face to face at a location
of the interviewee’s choice, but virtual modes will be
considered for logistical reasons. All proceedings will be
audio recorded and transcribed verbatim. Thematic ana-
lysis will draw on the NPT framework, but an inductive
approach will enable recognition of unexpected emer-
gent themes. Data will be managed in NVIVO.
Documentary evidence
Minutes of meetings will provide researcher-reported in-
formation on barriers, facilitators and other confounding
factors that may have affected delivery of the trial, e.g.
(recruitment challenges, reach).
Data integration/synthesis
Once all process and main trial outcomes are reported, all
the data sets (qualitative and quantitative) will be inte-
grated [19] using a triangulation approach to consider
agreement, partial agreement, silence and dissonance
across the findings. This will identify relevant actions, and
clarify and relate causal pathways to experiences, provid-
ing an enriched means to explain unexpected outcomes,
and identify optimal intervention contexts. Should the
main RCT findings suggest the CHIPPS service is effective
and efficient, the process evaluation will inform recom-
mendations for implementation into routine services. The
process evaluation will also be interrogated to understand
reasons why the intervention has not been successful, in-
cluding variable success rates in different sites.
Discussion
This detailed mixed-method process evaluation will pro-
vide an in-depth understanding of the interactions, bar-
riers and facilitators which underpin the main study
quantitative findings. For example, it will provide evi-
dence of the effectiveness of the training in preparing
the PIPs to deliver their role, show to what extent the
mechanism of impact – improved medication manage-
ment – has been implemented and the barriers and facil-
itators that have been encountered. Learning from these
will enable decisions to be made about future roll-out of
the PIP service. Further, if the main trial does not dem-
onstrate that there has been an improvement in patient
outcomes, it will allow an informed judgement to be
made as to whether the service is wrong in principle or
whether its implementation has been suboptimal. Our
findings will be especially pertinent and timely as PIPs
are already being introduced into care homes for roles
such as we are evaluating. The systematic and compre-
hensive approach that is being adopted is in line with
the MRC guidance on process evaluations [14, 15]. It
will ensure data is captured on all aspects of the study,
and allow an understanding of the implementation of
the service, confirm its mechanism of impact, explore
secondary, possibly explanatory, outcomes and any con-
textual factors. In summary, with so many interrelated
factors involved it is important that a process evaluation
is undertaken to enable identifyimg which elements of
the service were deemed to be effective and explain any
differences seen whilst also identifying adaptions, en-
ablers and barriers.
Trial status
Resident recruitment for the RCT began in February
2018 and will continue until October 2019. Recruitment
for the process evaluation started spring 2019 and will
continue until June 2020.
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